I am a
Home I AM A Search Login

Papers of the Week

Papers: 9 Jan 2021 - 15 Jan 2021

Pharmacology/Drug Development


2021 Jan 07

J Headache Pain



Immunogenicity of biologic therapies for migraine: a review of current evidence.


Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Ramirez Campos V, Seminerio MJ, Krasenbaum LJ, Shen H, Stratton J
J Headache Pain. 2021 Jan 07; 22(1):3.
PMID: 33413094.


Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical trials along with favorable safety and tolerability profiles. Although erenumab is a human mAb and the others have been humanized to varying degrees, they all have the capacity to provoke immune reactions. The present review article aims to discuss the current relationship between mAbs targeting the CGRP pathway (CGRP mAbs) and immunogenicity and their potential clinical implications.